Specialty medical injectable drug program, requirements and drug policy updates
New specialty medical injectable updates and requirements announced.
June 27, 2023
- All states
- Regulatory and compliance
Review the following tables to determine changes to our specialty medical injectable drug programs.
SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH
| Drug Name | UnitedHealthcare Commercial | Treatment Uses |
Elfabrio® (pegunigalsidase alfa-iwxj) |
X | For the treatment of adults with Fabry disease. |
QalsodyTM (tofersen) |
X | For the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
For questions, please contact your broker or UnitedHealthcare representative.
More updates for your clients
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.
Important, required notices for products, plans, forms and more.
Need-to-know operational announcements for you and your clients.